Established in March 2016, Coherent Biopharma (Suzhou) Co., Ltd.（CBP） is committed to the research, development and industrialization of tumor targeting ligand conjugate drugs and tumor biomarker diagnostic reagents.. Rich experience in new drug research and development management at home and abroad. The company’s management team is composed of several outstanding biological R&D, medicinal chemistry/CMC, preclinical, and clinical experts, including two experts awarded with national key talent introduction project, one expert with the title of Jiangsu provincial innovation high-level talents. All members of the management team have extensive experience in major domestic and overseas drug companies. CBP has developed a wide range of product pipelines based on its own Bi-Engaging ligand-mediated Selective Targeting platform (BESTTM). The first product, CBP-1008, has obtained China's clinical approval and US FDA's clinical trial approval, and Phase I clinical study is on-going. The second product CBP-1018, has obtained the NMPA clinical trial approval from NMPA recently. Several other new drug candidates are at various stages of product development. They will enter clinical phase in the next few years.